Streetwise Reports' Article Archives — February 2019 back to current month (14)

Biotech to Launch Preclinical Studies of Antibody in Eight Cancer Types (02/27/2019)

This company's new trials, preferred dosing and upcoming biologics license application submission are discussed in an H.C. Wainwright & Co. report.

more>

FDA Grants Breakthrough Status to Biopharma's Lead Candidate for Liver Disease (02/25/2019)

The California firm's most advanced asset is advancing through Phase 2b, according to a ROTH Capital Partners report.

more>

Livestock Feed Developer Partners to Initiate Product Sales in the U.S. (02/22/2019)

The arrangement represents this Canadian life sciences firm's entrée into a significant market.

more>

Biopharma's Foundation Provides for Downside Protection, Upside Realization (02/20/2019)

An H.C. Wainwright & Co. report described this Israeli firm's solid revenue picture and addressed the undervaluation of a key therapeutic candidate.

more>

Canadian Company Completes Two Cannabis Harvests (02/17/2019)

The firm also makes progress in obtaining technology rights and various licenses.

more>

Bringing Advanced Technology to the Cannabis Space (02/13/2019)

This cannabis technology company brings artificial intelligence, blockchain and cryptocurrency to the global medical cannabis marketplace to help patients make informed decisions and drive medical cannabis sales.

more>

Biotech Identifies Antibody Drug Candidates to Target Toxic Protein Implicated in Parkinson's Disease (02/13/2019)

The Canadian company continues seeking partners to leverage its discovery and development platform.

more>

Clinical Movement Expected in 2019 on Pharma Firm's 'Gene Therapy Promise' (02/13/2019)

A number of data readouts are expected in the coming months, which could derisk and accelerate development programs, according to an H.C. Wainwright & Co. report.

more>

Report Highlights Biopharma's Breakthroughs on Treatment of Life-Threatening Pediatric Liver Diseases (02/13/2019)

Analyst expects "transformational year" for company with a phase 3 trial underway.

more>

Biopharma's Drug Well Tolerated in Opioid Withdrawal Study (02/09/2019)

An H.C. Wainwright & Co. discussed these proof-of-concept data and described the company's planned Phase 1 study.

more>

Medical Device Firm Develops Nitric Oxide Delivery Unit for Clinic Use (02/06/2019)

This new machine takes the company's product line count to four.

more>

Is Elixinol the Fastest Growing Hemp/CBD Producer? (02/04/2019)

Fincom Investment Partners discusses Elixinol's Q4 earnings, previews Charlotte's Web and CV Sciences' earnings, and compares the three companies.

more>

Accelerated Approval Could Be 'Game Changer' for Biotech (02/02/2019)

This Canadian company's immunotherapeutic targeting ovarian cancer could advance to market sooner, according to a Mackie Research Capital Corp. note.

more>

Biotech Offers Reason for Others' Failed Trials of Potential Alzheimer's Disease Treatments (02/02/2019)

This Canadian developer of therapeutics for neurodegenerative diseases bases its opinion, in part, on its own preclinical findings.

more>

More Archives

2019Aug Jul Jun May Apr Mar Feb Jan

2018Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2017Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2016Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2015Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2014Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Notable Quotes

"DRRX earned a $10M milestone payment from Gilead."
– Ed Arce, H.C. Wainwright & Co.